RxDoctor Payments Data

Lindsay Adam, MD

Ophthalmology · Raleigh, NCNPI 1427360783

Payments from drug & device makers

$1,774in general payments, 2019–2025

Across 42 payments — averaging $42.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Ocular Therapeutix, Inc.$89
  • Sun Pharmaceutical Industries Inc.$84
  • Novartis$76
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$68
  • Bausch & Lomb Americas Inc.$63
  • plus $221 from 7 others

What the payments were for

  • Food & beverage$1,774100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,774 in reported general payments places this provider in the 50th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$227,945
Medicare patients
954
Services billed
1,836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine60$79,592
VyzultaLatanoprostene Bunod38$17,554
Cyclosporine19$5,484
Dorzolamide-TimololDorzolamide/Timolol/Pf21$4,598
Prednisolone Acetate104$3,456
LumiganBimatoprost12$2,987
Latanoprost143$2,614
Fluorometholone33$2,579
Brimonidine Tartrate43$2,002
Tobramycin-DexamethasoneTobramycin/Dexamethasone46$1,984
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat77$1,211
Timolol Maleate65$1,158
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha49$608
ErythromycinErythromycin Base44$515
MoxifloxacinMoxifloxacin Hcl14$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$46$82,57872 claims
Bausch & Lomb Americas Inc.Vyzulta$63$17,55438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →